Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT known ✓ | P10721 | 1/20 | 0.53 |
| ▸ | CSF1R | P07333 | 11/20 | 0.53 |
| ▸ | FLT3 | P36888 | 1/20 | 0.53 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL18297747 | 0.97 | CSF1R (0.52) | CSF1RKITFLT3TBK1 | |
| SCHEMBL3657513 | 0.95 | CSF1R (0.55) | CSF1RKITFLT3TBK1 | |
| Hydrochloric Acid SCHEMBL3657154 | 0.94 | CSF1R (0.54) | CSF1RKITFLT3TBK1 | |
| SCHEMBL3659610 | 0.88 | CSF1R (0.54) | CSF1RKITFLT3TBK1TRPV1 | |
| Sulfuric Acid SCHEMBL18297749 | 0.85 | CSF1R (0.53) | CSF1RKITFLT3TBK1 | |
| SCHEMBL3657224 | 0.84 | CSF1R (0.42) | CSF1RKITFLT3 | |
| SCHEMBL3703950 | 0.83 | CSF1R (0.43) | CSF1RKITFLT3TBK1 | |
| SCHEMBL3653202 | 0.80 | CSF1R (0.53) | CSF1RKITFLT3TBK1 | |
| SCHEMBL3656496 | 0.80 | CSF1R (0.40) | CSF1RKITFLT3TBK1 | |
| Trifluoroacetic Acid SCHEMBL3652052 | 0.80 | CSF1R (0.42) | CSF1RKITFLT3TBK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3208269-B1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-15 | — | — | EP | claimed |
| EP-3208269-A1 | INHIBITORS OF C-FMS KINASE | Janssen Pharmaceutica N.V. (BE) | 2017-08-23 | — | — | EP | claimed |
| US-8497376-B2 | 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-07-30 | — | — | US | claimed |
| EP-2215079-A1 | INHIBITORS OF C-FMS KINASE | Janssen Pharmaceutica N.V. (BE) | 2010-08-11 | — | — | EP | claimed |
| WO-2009052237-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-04-23 | — | — | WO | claimed |
| EP-3208269-B1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-15 | — | — | EP | disclosed |
| EP-3208269-A1 | INHIBITORS OF C-FMS KINASE | Janssen Pharmaceutica N.V. (BE) | 2017-08-23 | — | — | EP | disclosed |
| EP-2215079-B1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2016-12-14 | — | — | EP | disclosed |
| US-20150232439-A1 | PROCESS FOR THE PREPARATION OF C-FMS KINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-08-20 | — | — | US | disclosed |
| US-9029352-B2 | Process for the preparation of C-FMS kinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-05-12 | — | — | US | disclosed |
| US-20140045789-A1 | PROCESS FOR THE PREPARATION OF C-FMS KINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-02-13 | — | — | US | disclosed |
| EP-2215079-A1 | INHIBITORS OF C-FMS KINASE | Janssen Pharmaceutica N.V. (BE) | 2010-08-11 | — | — | EP | disclosed |
| WO-2009052237-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232439-A1 | PROCESS FOR THE PREPARATION OF C-FMS KINASE INHIBITORS | FLT3, FES, FER | KIT 24/4885CSF1R 76/4885FLT3 1/4885 |
| US-20140045789-A1 | PROCESS FOR THE PREPARATION OF C-FMS KINASE INHIBITORS | FLT3, FES, FER | KIT 24/4885CSF1R 76/4885FLT3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.